News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,903 Results
Type
Article (14929)
Company Profile (300)
Press Release (266668)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79909)
Career Advice (162)
Deals (13353)
Drug Delivery (39)
Drug Development (50779)
Employer Resources (31)
FDA (5843)
Job Trends (5178)
News (145238)
Policy (10091)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (927)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21792)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6037)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4571)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3129)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43719)
Collaboration (1148)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1110)
CRISPR (86)
C-suite (550)
Cystic fibrosis (113)
Data (4316)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1381)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31677)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51696)
Executive appointments (621)
FDA (7590)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (486)
GLP-1 (504)
Government (1151)
Grass and pollen (3)
Guidances (166)
Healthcare (6618)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1214)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (168)
Interviews (18)
IPO (7359)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (244)
Leadership (9)
Legal (1402)
Liver cancer (41)
Longevity (11)
Lung cancer (419)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (130)
Medical device (2665)
Medtech (2674)
Mergers & acquisitions (6617)
Metabolic disorders (724)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1950)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (867)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (304)
Patient recruitment (327)
Peanut (43)
People (26662)
Pharmaceutical (45)
Pharmacy benefit managers (6)
Phase 1 (15496)
Phase 2 (20316)
Phase 3 (12831)
Pipeline (3240)
Policy (90)
Postmarket research (854)
Preclinical (6546)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (648)
Real estate (1447)
Recruiting (12)
Regulatory (9905)
Reports (19)
Research institute (974)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (124)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (6)
Last 7 days (344)
Last 30 days (1300)
Last 365 days (17838)
2026 (1651)
2025 (18105)
2024 (20564)
2023 (22452)
2022 (26865)
2021 (27885)
2020 (23398)
2019 (16233)
2018 (11746)
2017 (13751)
2016 (11846)
2015 (14360)
2014 (10402)
2013 (7491)
2012 (7535)
2011 (7620)
2010 (7434)
Location
Africa (155)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18266)
Australia (3112)
California (7078)
Canada (1836)
China (772)
Colorado (247)
Connecticut (252)
Delaware (235)
Europe (39253)
Florida (903)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (396)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5583)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1760)
North Carolina (825)
North Dakota (7)
Northern California (3476)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2807)
Tennessee (40)
Texas (904)
United States (23333)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,903 Results for "ribon therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Big Pharma-Backed Ribon Therapeutics Shuts Down Business Operations
Despite having an impressive roster of high-profile supporters, including AbbVie, BMS, J&J, Novartis and Pfizer, PARP-focused Ribon has called it quits after nearly a decade in business.
August 5, 2024
·
2 min read
·
Tristan Manalac
Business
Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer
Ribon Therapeutics, a clinical-stage biotechnology company developing therapeutics to target stress support pathways, today announced a $25 million investment from Pfizer.
January 30, 2023
·
2 min read
Deals
Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim
Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that it entered into an agreement on the acquisition of its CD38 program with Boehringer Ingelheim.
November 29, 2022
·
2 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Drug Development
Ribon Therapeutics Doses First Patient in Phase 1 Clinical Study with RBN-3143 in Patients with Moderate-to-Severe Atopic Dermatitis
Ribon Therapeutics today announced dosing the first patient in the open-label cohort of patients with moderate-to-severe atopic dermatitis to measure the pharmacodynamic activity of RBN-3143 and evaluate the safety and preliminary efficacy of 28 days of administration of RBN-3143 in this target population.
March 9, 2023
·
3 min read
Genetown
Ribon Therapeutics Secures $65 Million Financing
Ribon Therapeutics announced the closing of a $65 million financing.
July 14, 2021
·
2 min read
Genetown
Ribon Therapeutics Announces Late-Breaking Presentation of Preclinical Data on RBN-3143 at the European Respiratory Society International Congress 2022
Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced in a late-breaking presentation, compelling preclinical data for RBN-3143, a novel, orally administered, first-in-class inhibitor of PARP14 with potential in a range of inflammatory diseases.
September 6, 2022
·
4 min read
Business
Ribon Therapeutics Announces Key Management Promotions
Ribon Therapeutics today announced the promotions of Heike Keilhack, Ph.D., to Chief Scientific Officer and Kevin Kuntz, Ph.D., to Chief Drug Development Officer.
September 1, 2021
·
3 min read
Genetown
Ribon Therapeutics Announces Presentations at the American Association for Cancer Research 2022 Annual Meeting
Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that an oral presentation and poster presentation for RBN-2397, the Company’s lead development candidate, was presented today, April 11, 2022, at the American Association for Cancer Research (AACR) Annual Meeting 2022 taking place in New Orleans, Louisiana.
April 11, 2022
·
4 min read
Business
Ribon Therapeutics Appoints Paul Brannelly as Chief Financial Officer
Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, announced the appointment of Paul Brannelly as Chief Financial Officer.
June 28, 2021
·
3 min read
1 of 28,191
Next
